InMode (NASDAQ:INMD) and CONMED (NYSE:CNMD) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, analyst recommendations, earnings, dividends, profitability, institutional ownership and valuation.

Analyst Ratings

This is a summary of recent recommendations and price targets for InMode and CONMED, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
InMode 0 0 4 0 3.00
CONMED 0 2 4 0 2.67

InMode currently has a consensus price target of $47.75, indicating a potential downside of 13.53%. CONMED has a consensus price target of $94.60, indicating a potential downside of 19.20%. Given InMode’s stronger consensus rating and higher possible upside, analysts plainly believe InMode is more favorable than CONMED.

Earnings and Valuation

This table compares InMode and CONMED’s top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
InMode $156.36 million 11.29 $61.15 million $1.60 34.51
CONMED $955.10 million 3.51 $28.62 million $2.64 44.35

InMode has higher earnings, but lower revenue than CONMED. InMode is trading at a lower price-to-earnings ratio than CONMED, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares InMode and CONMED’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
InMode 32.57% 28.56% 24.14%
CONMED 0.04% 9.48% 3.75%

Insider and Institutional Ownership

27.7% of InMode shares are owned by institutional investors. 5.4% of CONMED shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Risk & Volatility

InMode has a beta of 1.96, indicating that its stock price is 96% more volatile than the S&P 500. Comparatively, CONMED has a beta of 1.55, indicating that its stock price is 55% more volatile than the S&P 500.

Summary

InMode beats CONMED on 10 of the 13 factors compared between the two stocks.

About InMode

InMode Ltd. designs, develops, manufactures, and markets minimally-invasive aesthetic medical products based on its proprietary radio frequency assisted lipolysis and deep subdermal fractional radio frequency technologies. The company offers minimally-invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments. It also designs, develops, manufactures, and markets non-invasive medical aesthetic products that target an array of procedures, including permanent hair reduction, facial skin rejuvenation, wrinkle reduction, cellulite treatment, skin appearance and texture, and superficial benign vascular and pigmented lesions. InMode Ltd. offers its products directly in the United States, Canada, the United Kingdom, Spain, Australia, and India, as well as indirectly through distributors in 46 countries. The company was formerly known as Invasix Ltd. and changed its name to InMode Ltd. in November 2017. InMode Ltd. was founded in 2008 and is headquartered in Yokneam, Israel.

About CONMED

CONMED Corporation, a medical technology company, develops, manufactures, and sells surgical devices and related equipment for minimally invasive procedures worldwide. The company offers orthopedic surgery products, including sports medicine products comprising powered resection instruments, arthroscopes, reconstructive systems, tissue repair sets, and metal and bioabsorbable implants, as well as related disposable products and fluid management systems; powered surgical instruments for use in bone orthopedic, arthroscopic, oral/maxillofacial, podiatric, spinal, and cardiothoracic surgeries; sports biologics and tissue products; and surgical visualization products. It offers orthopedic surgery products under Hall, CONMED Linvatec, Concept, and Shutt brands. The company also offers general surgery product in the areas of advanced surgical comprising clinical insufflation system; electrosurgical products; and endomechanical products comprising instruments, such as tissue retrieval bags, trocars, suction irrigation devices, graspers, scissors, and dissectors. In addition, it offers endoscopic technologies offering, including diagnostic and therapeutic products for use in gastroenterology procedures; cardiology and critical care products cover a line of vital signs, cardiac monitoring, and patient care products, including ECG electrodes and accessories, cardiac defibrillation and pacing pads, and suction instruments and tubing; and physician's office electrosurgical product used by dermatologists. The company markets its products directly to surgeons, hospitals, surgery centers, group purchasing organizations, integrated delivery networks, and other customers, as well as through medical specialty distributors. CONMED Corporation was founded in 1970 and is headquartered in Utica, New York.

Receive News & Ratings for InMode Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InMode and related companies with MarketBeat.com's FREE daily email newsletter.